Inclusion Criteria:

- Patients must have histologically or cytologically confirmed advanced cancer that is:

- HER2 amplified (IHC 2+ or greater) based on archived tumor evaluation

- Heregulin positive based on a study required fresh biopsy sample performed at
screening and confirmed by central laboratory

- Patients must have blocks of archived formalin-fixed, paraffin-embedded tumor tissue
available for sectioning and immunohistochemical staining

- Patient's cancer must have recurred or progressed following standard therapy, have
not responded to standard therapy, or for which no standard therapy exists.

- Patients must be >= 18 years of age

- Patients or their legal representatives must be able to understand and sign an
informed consent

- Patients may have measurable or non-measurable tumor(s)

- Patients should have ECOG Performance Score (PS) 0 or 1

- Patients must have adequate bone marrow reserves as evidenced by:

- Absolute neutrophil count (ANC) >= 1,500/uL and

- Platelet count >= 100,000/uL

- Hemoglobin >= 9 g/dL

- Patients must have tumor tissue amenable to biopsy

- Patients must be willing to undergo biopsy prior to treatment to MM-111

Exclusion Criteria:

- Patients for whom potentially curative antineoplastic therapy is available

- Patients who are pregnant or lactating

- Patients with an active infection or with an unexplained fever greater than 38.5 C
during screening visits or on the first scheduled day of dosing. (At the discretion
of the investigator, patients with tumor fever may be enrolled)

- Patients with untreated and/or symptomatic primary or metastatic CNS malignancies
(patients with CNS metastases who have undergone surgery or radiotherapy, whose
disease is stable, and who have been on a stable dose of corticosteroids for at least
2 weeks prior to the first scheduled day of dosing will be eligible for the trial

- Patients with known hypersensitivity to any of the components of MM-111 or who have
had hypersensitivity reactions to fully human monoclonal antibodies (patients with a
history of hypersensitivity to trastuzumab, a humanized antibody, are not excluded)

- Patients with known HIV, hepatitis B or C (if patients have previously been treated
for C and have undetectable viral loads, they can be considered eligible for the
trial)